Kenvue IPO
Kenvue is a consumer health company that owns iconic brands including Johnson's Baby, Neutrogena, Tylenol, Band-Aid, and Listerine. The company was spun off from Johnson & Johnson to focus exclusively on consumer health products including over-the-counter medications, skincare, and personal care items. Investors were attracted to the stable cash flows and strong brand recognition of its consumer health portfolio.
What We Know
Kenvue went public in May 2023 through one of the largest IPOs of that year, raising approximately $3.8 billion. The company was spun off from Johnson & Johnson as part of J&J's strategy to separate its consumer health business from its pharmaceutical and medical device operations. Kenvue priced its shares at $22 each in the initial offering. The company trades on the NYSE under ticker symbol "KVUE" and has focused on growing its consumer health brands globally while investing in e-commerce and direct-to-consumer channels. Since going public, Kenvue has operated as an independent consumer health company with a portfolio of well-established brands.
Frequently Asked Questions
Has Kenvue had an IPO?
Yes, Kenvue completed its IPO in May 2023, spinning off from Johnson & Johnson to become a standalone public company. It was one of the largest IPOs of 2023.
When is the Kenvue IPO date?
Kenvue's IPO already occurred in May 2023 when the consumer health company went public. The company successfully separated from J&J and began independent trading.
How can I buy Kenvue stock?
You can buy Kenvue stock through any brokerage account as the company trades on the NYSE under ticker symbol "KVUE." The stock is widely available through brokers and trading platforms.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts